SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 151.26 |
| Enterprise Value ($M) | 218.98 |
| Book Value ($M) | 48.88 |
| Book Value / Share | 0.27 |
| Price / Book | 3.09 |
| NCAV ($M) | 27.40 |
| NCAV / Share | 0.15 |
| Price / NCAV | 5.52 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.66 |
| Return on Assets (ROA) | -0.42 |
| Return on Equity (ROE) | -1.28 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.24 |
| Current Ratio | 4.24 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 286.48 |
| Assets | 307.97 |
| Liabilities | 259.08 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Samlyn Capital, Llc | 5.20 | ||
| 13G/A | Deep Track Capital, LP | 1.07 | -87.59 | |
| 13G/A | Eventide Asset Management, Llc | 3.61 | -29.26 | |
| 13G | BlackRock, Inc. | 8.70 | 0.00 | |
| 13G | TCG Crossover GP II, LLC | 9.90 | ||
| 13G/A | Citadel Advisors Llc | 3.00 | ||
| 13G/A | Ra Capital Management, L.p. | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 6.31 | -0.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 213,233 | 1,230,369 | 17.33 | |
| 297,761 | 1,232,608 | 24.16 | |
| 149,750 | 731,554 | 20.47 | |
| 211,274 | 1,313,624 | 16.08 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MYNZ – Mainz Biomed N.V. | NATR – Nature's Sunshine Products, Inc. |
| NERV – Minerva Neurosciences, Inc. | NLSP – NLS Pharmaceutics AG |
| NRSN – NeuroSense Therapeutics Ltd. |
Financial data and stock pages provided by
Fintel.io